Izumerogant

Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties[1][2].

Product Specifications

CAS Number

[2299252-72-3]

Product Name Alternative

IMU-935

UNSPSC

12352005

Target

CMV; Dihydroorotate Dehydrogenase; ROR; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/izumerogant.html

Purity

99.95

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

FC1=CC=CC(Cl)=C1C2=NOC(C3=C(C(F)(F)F)N(CCC(C)(C)O)N=C3)=C2C4=NC=CC=N4

Molecular Formula

C22H18ClF4N5O2

Molecular Weight

495.86

References & Citations

[1]F Jakob, et al. Isoxazole-pyrazole derivatives and related compounds as IL-17 and IFN-γ inhibitors for treating autoimmune diseases and chronic inflammation: World Intellectual Property Organization, WO2019048541. 2019-03-14.|[2]Polasek TM, et al. Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2023 May;12 (5) :525-534.